Factors predicting adverse short-term outcomes in patients with acute cholangitis undergoing ERCP: A single center experience

Table 2 Univariate analysis for adverse clinical outcome in 35 patients

Variable	OR (95%CI)	P value
Age	1.15 (1.02-1.30)	0.02
Male	0.90 (0.43-1.89)	0.78
Body mass index	1.23 (0.88-1.71)	0.23
Smoking	0.62 (0.22-1.72)	0.36
Primary sclerosing cholangitis	0.27 (0.09-0.82)	0.02
Systemic inflammatory response syndrome	5.46 (2.34-12.73)	< 0.001
Charlson comorbidity index	1.02 (0.85-1.23)	0.04
American Society of Anesthesiology physical classification	6.94 (3.14-15.33)	< 0.001
Altered mental status	1.31 (0.25-6.80)	0.61
Statins at admission	2.32 (0.97-5.57)	0.06
Anti-platelets meds at admission	2.18 (0.93-5.07)	0.07
Door to ERCP timing (> 72 h)	2.03 (0.83-4.95)	0.12
Pre-ERCP Bilirubin	1.05 (0.98-1.12)	0.20
Positive blood cultures	1.79 (0.79-4.10)	0.17
Presence of fever	2.87 (1.17-7.04)	0.02
Post ERCP bleeding	4.00 (0.24-65.59)	0.37
Presence of purulent bile at ERCP	1.41 (0.45 -5.40)	0.73
Transfer patients	0.72 (0.32-1.59)	0.41

ERCP: Endoscopic retrograde cholangiopancreatography.